US FDA notes 22 observations at Lupin’s Indian base

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Andrey_Kuzmin)
(Image: Getty/Andrey_Kuzmin)

Related tags Lupin Pharmaceuticals Fda cephalosporin

Lupin has received 22 observations across three facilities at its Mandideep campus, which the company says are only ‘procedural in nature’.

The US Food and Drug Administration (FDA) carried out inspections between November 26 and December 4, 2018.

The Mandideep facilities produce active pharmaceutical ingredients (APIs) for its blood pressure drugs, as well as APIs for, and solid oral dosage forms of, cephalosporin – a first line antibiotic.

The company noted, “The inspection at Unit-1, the cephalosporin facilities, closed with 10 observations for the cephalosporin API facilities and eight observations for the cephalosporin Solid Oral Dosage Form facility.

“The inspection at Unit-2, the Cardiovascular ‘Pril’ API facilities, closed with four observations,” ​the statement continued.

While Lupin suggested​ the observations were “largely procedural in nature”​, the FDA did identify gaps in the aseptic processing areas of the cephalosporin API block.

The company is already working to address the issues, with a ‘Quality Management System and Compliance Sustainability Plan’ underway to address some of the issues raised by the FDA.

A spokesperson for Lupin stated that no further details could be revealed about the inspection outcomes.

During an August inspection​ this year, the FDA also detected procedural issues at Lupin’s facility in Tarapur, India. The inspection was prompted by valsartan contamination concerns in the EU and US, an issue that is still causing global recalls​.

However, Lupin’s facilities were found to pose no risk for ‘sartan’ contamination.

Related news

Show more

Related products

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us


View more